Auriane Gros

Auriane Gros

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Auriane Gros has a total of 57 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Dynamics of oral language and speech production through neuromodulation: A systematic review of non-invasive brain stimulation in neurodegeneration

    by Eloïse Da Cunha, Silke Coemans, Stefanie Keulen, Cordélia Fauvet, Raphaël Zory, Valeria Manera, Auriane Gros


  • Open Access

    Assessing the Recognition of Social Interactions Through Body Motion in the Routine Care of Patients with Post-Lingual Sensorineural Hearing Loss

    by Cordélia Fauvet, Léa Cantini, Aude-Eva Chaudoreille, Elisa Cancian, Barbara Bonnel, Chloé Sérignac, Alexandre Derreumaux, Philippe Robert, Nicolas Guevara, Auriane Gros, et al.

    Background: Body motion significantly contributes to understanding communicative and social interactions, especially when auditory information is impaired. The visual skills of people with hearing loss are often enhanced and compensate for some of the missing auditory information. In the present study, we investigated the recognition of social interactions by observing body motion in people with post-lingual sensorineural hearing loss (SNHL). Methods: In total, 38 participants with post-lingual SNHL and 38 matched normally hearing individuals (NHIs) were presented with point-light stimuli of two agents who were either engaged in a communicative interaction or acting independently. They were asked to classify the actions as communicative vs. independent and to select the correct action description. Results: No significant differences were found between the participants with SNHL and the NHIs when classifying the actions. However, the participants with SNHL showed significantly lower performance compared with the NHIs in the description task due to a higher tendency to misinterpret communicative stimuli. In addition, acquired SNHL was associated with a significantly higher number of errors, with a tendency to over-interpret independent stimuli as communicative and to misinterpret communicative actions. Conclusions: The findings of this study suggest a misinterpretation of visual understanding of social interactions in individuals with SNHL and over-interpretation of communicative intentions in SNHL acquired later in life.

  • Open Access

    Evaluation of the Cognitive Function of Adults with Severe Hearing Loss Pre- and Post-Cochlear Implantation Using Verbal Fluency Testing

    by Manon Baranger, Valeria Manera, Chloé Sérignac, Alexandre Derreumaux, Elisa Cancian, Clair Vandersteen, Auriane Gros, Nicolas Guevara

    Hearing loss is a major public health problem with significant evidence correlating it with cognitive performance. Verbal fluency tests are commonly used to assess lexical access. They provide a great deal of information about a subject’s cognitive function. The aim of our study was to evaluate phonemic and semantic lexical access abilities in adults with bilateral severe to profound hearing loss and then to re-evaluate a cohort after cochlear implantation. 103 adult subjects underwent phonemic and semantic fluency tests during a cochlear implant candidacy evaluation. Of the total 103 subjects, 43 subjects underwent the same tests at 3 months post-implantation. Our results showed superior performance in phonemic fluency compared to semantic fluency in subjects prior to implantation. Phonemic fluency was positively correlated with semantic fluency. Similarly, individuals with congenital deafness had better semantic lexical access than individuals with acquired deafness. Results at 3 months post-implantation showed an improvement in phonemic fluency. No correlation was found between the evolution of pre- and post-implant fluency and the auditory gain of the cochlear implant, and we found no significant difference between congenital and acquired deafness. Our study shows an improvement in global cognitive function after cochlear implantation without differentiation of the phonemic-semantic pathway.


  • Open Access

    A video game for emotion regulation of medical students

    by Maël Addoum, Loïc Jacob, Yannick Bourquin, Aurélien Lherbier, Auriane Gros, Philippe Robert

    Depression among students has increased due to the COV-ID-19 epidemic (remote learning, lockdowns, isolation, etc.), especially those who suffer from cognitive dysfunction. Teachers in the health fields regret that emotional regulation methods are not sufficiently taught in France. In this study, we design a pedagogical Ludo application that cares about the mental health of medical students throughout their studies. This application called, TeachMod RE, aims thus to learn how to regulate students' negative emotions.

  • Open Access

    Logogenic Primary Progressive Aphasia or Alzheimer Disease: Contribution of Acoustic Markers in Early Differential Diagnosis

    by Eloïse Da Cunha, Alexandra Plonka, Seçkin Arslan, Aurélie Mouton, Tess Meyer, Philippe Robert, Fanny Meunier, Valeria Manera, Auriane Gros

    The logopenic variant of Primary Progressive Aphasia (lvPPA), a syndromic disorder centered on language impairment, often presents variable underlying neurodegenerative pathologies such as Alzheimer Disease (AD). Actual language assessment tests and lumbar puncture, focused on AD diagnosis, cannot precisely distinguish the symptoms, or predict their progression at onset time. We analyzed acoustic markers, aiming to discriminate lvPPA and AD as well as the influence of AD biomarkers on acoustic profiles at the beginning of the disease. We recruited people with AD (n = 8) and with lvPPA (n = 8), with cerebrospinal fluid biomarker profiles determined by lumbar puncture. The participants performed a sentence repetition task that allows assessing potential lvPPA phonological loop deficits. We found that temporal and prosodic markers significantly differentiate the lvPPA and AD group at an early stage of the disease. Biomarker and acoustic profile comparisons discriminated the two lvPPA subgroups according to their biomarkers. For lvPPA with AD biomarkers, acoustic profile equivalent to an atypical AD form with a specific alteration of the phonological loop is shown. However, lvPPA without AD biomarkers has an acoustic profile approximating the one for DLFT. Therefore, these results allow us to classify lvPPA differentially from AD based on acoustic markers from a sentence repetition task. Furthermore, our results suggest that acoustic analysis would constitute a clinically efficient alternative to refused lumbar punctures. It offers the possibility to facilitate early, specific, and accessible neurodegenerative diagnosis and may ease early care with speech therapy, preventing the progression of symptoms.


  • Open Access

    Olfactory Training in Post-COVID-19 Persistent Olfactory Disorders: Value Normalization for Threshold but Not Identification

    by Clair Vandersteen, Magali Payne, Louise-Émilie Dumas, Élisa Cancian, Alexandra Plonka, Grégoire D’andréa, David Chirio, Élisa Demonchy, Karine Risso, Florence Askenazy-Gittard, et al.

    (1) Background: Persistent post-viral olfactory disorders (PPVOD) are estimated at 30% of patients one year after COVID-19 infection. No treatment is, to date, significantly effective on PPVOD with the exception of olfactory training (OT). The main objective of this work was to evaluate OT efficiency on post-COVID-19 PPVOD. (2) Methods: Consecutive patients consulting to the ENT department with post-COVID-19 PPVOD were included after completing clinical examination, the complete Sniffin’ Stick Test (TDI), the short version of the Questionnaire of olfactory disorders and the SF-36. Patients were trained to practice a self-olfactory training with a dedicated olfactory training kit twice a day for 6 months before returning to undergo the same assessments. (3) Results: Forty-three patients were included and performed 3.5 months of OT in average. We observed a significant TDI score improvement, increasing from 24.7 (±8.9) before the OT to 30.9 (±9.8) (p < 0.001). Based on normative data, a significant increase in the number of normosmic participants was observed only for the threshold values (p < 0.001). Specific and general olfaction-related quality of life improved after the OT. (4) Conclusions: Olfactory function appeared to improve only in peripheral aspects of post-COVID-19 PPVOD after OT. Future controlled studies must be performed to confirm the OT role and justify new therapeutic strategies that may focus on the central aspects of post-COVID-19 PPVOD.


  • Open Access

    Correlations between Persistent Olfactory and Semantic Memory Disorders after SARS-CoV-2 Infection

    by Julie Fiorentino, Magali Payne, Elisa Cancian, Alexandra Plonka, Louise-Émilie Dumas, David Chirio, Élisa Demonchy, Karine Risso, Florence Askenazy-Gittard, Nicolas Guevara, et al.

    Background: One of the main symptoms of COVID-19 is hyposmia or even anosmia. Olfactory identification is most often affected. In addition, some cognitive disorders tend to appear following the infection, particularly regarding executive functions, attention, and memory. Olfaction, and especially olfactory identification, is related to semantic memory which manages general knowledge about the world. The main objective of this study was to determine whether semantic memory is impaired in case of persistent post COVID-19 olfactory disorders. Methods: 84 patients (average age of 42.8 ± 13.6 years) with post COVID-19 olfactory loss were included after consulting to the ENT department. The clinical evaluation was carried out with the Pyramid and Palm Tree Test, the word-retrieval task from the Grémots, the Sniffin’ Sticks Test and the Computerised Olfactory Test for the Diagnosis of Alzheimer’s Disease. Results: Semantic memory was impaired in 20% (n = 17) of patients, especially in the 19–39 age-group. The olfactory threshold was only significantly correlated with the semantic memory scores. Conclusions: Similar to all cognitive disorders, semantic disorders can have a negative impact on quality of life if left untreated. It is essential to carry out specific assessments of post COVID-19 patients to accurately determine their disorders and to put in place the best possible rehabilitation, such as speech and language therapy, to avoid quality-of-life impairment.


  • Open Access

    The course of primary progressive aphasia diagnosis: a cross-sectional study

    by A. Mouton, A. Plonka, R. Fabre, T. M. Tran, P. Robert, J. Macoir, V. Manera, A. Gros

    Background: The primary progressive aphasia (PPA) diagnosis trajectory is debated, as several changes in diagnosis occur during PPA course, due to phenotype evolution from isolated language alterations to global cognitive impairment.The goal of the present study, based on a French cohort, was to describe the demographics and the evolution of subjects with (PPA) in comparison with Alzheimer’s disease (AD) on a period of 7 years.Methods: We conducted a repeated cross-sectional study. The study population comprised individuals with PPA and AD diagnosis (N=167,191) from 2010 to 2016 in the French National data Bank (BNA). Demographic variables, MMSE scores, diagnosis status at each visit and prescribed treatments were considered.Results: From 2010 to 2016, 5186 patients were initially diagnosed with PPA, 162,005 with AD. Compared to AD subjects, significant differences were found concerning age (younger at first diagnosis for PPA), gender (more balanced in PPA), education level (higher in PPA) and MMSE score (higher of 1 point in PPA).Percentage of pending diagnosis, delay between first consultation and first diagnosis and the number of different diagnoses before the diagnosis of interest were significantly higher in PPA group compared to AD group. Pharmacological and non-pharmacological treatments were significatively more recommended following PPA than AD diagnosis.Conclusion: This study improves the knowledge of PPA epidemiology and has the potential to help adopting appropriate public health service policies. It supports the hypothesis that PPA is diagnosed later than AD. The PPA diagnosis increases the prescription of non-pharmacological treatments, especially speech and language therapy (SLT) that is the main treatment available and most effective when at the initial stage.Trial registration: ClinicalTrials.gov identifierNCT03687112


  • Open Access

    Primary Progressive Aphasia: Use of Graphical Markers for an Early and Differential Diagnosis

    by Alexandra Plonka, Aurélie Mouton, Joël Macoir, Thi-Mai Tran, Alexandre Derremaux, Philippe Robert, Valeria Manera, Auriane Gros

    Primary progressive aphasia (PPA) brings together neurodegenerative pathologies whose main characteristic is to start with a progressive language disorder. PPA diagnosis is often delayed in non-specialised clinical settings. With the technologies’ development, new writing parameters can be extracted, such as the writing pressure on a touch pad. Despite some studies having highlighted differences between patients with typical Alzheimer’s disease (AD) and healthy controls, writing parameters in PPAs are understudied. The objective was to verify if the writing pressure in different linguistic and non-linguistic tasks can differentiate patients with PPA from patients with AD and healthy subjects. Patients with PPA (n = 32), patients with AD (n = 22) and healthy controls (n = 26) were included in this study. They performed a set of handwriting tasks on an iPad® digital tablet, including linguistic, cognitive non-linguistic, and non-cognitive non-linguistic tasks. Average and maximum writing pressures were extracted for each task. We found significant differences in writing pressure, between healthy controls and patients with PPA, and between patients with PPA and AD. However, the classification of performances was dependent on the nature of the tasks. These results suggest that measuring writing pressure in graphical tasks may improve the early diagnosis of PPA, and the differential diagnosis between PPA and AD.


  • Open Access

    The Course of Primary Progressive Aphasia Diagnosis : A Cross-Sectional Study.

    by Aurélie Mouton, Alexandra Plonka, Roxane Fabre, Maï Tran, Philippe Robert, Joel Macoir, Valeria Manera, Auriane Gros

    BackgroundThe Primary Progressive Aphasia (PPA) diagnosis trajectory is debated, as several changes in diagnosis occur during PPA course, due to phenotype evolution from isolated language alterations to global cognitive impairment.The goal of the present study, based on a French cohort was to describe the demographics and the evolution of subjects with (PPA) in comparison with Alzheimer Disease (AD) on a period of seven years. MethodsWe conducted a repeated cross-sectional study. The study population comprised individuals with PPA and AD diagnosis (N=167191) from 2010 to 2016 in the French National data Bank (BNA). Demographic variables, MMSE scores, diagnosis status at each visit and prescribed treatments were considered.ResultsFrom 2010 to 2016, 5186 patients were initially diagnosed with PPA, 162005 with AD. Compared to AD subjects, significant differences were found concerning: age (younger at first diagnosis for PPA), gender (more balanced in PPA), education level (higher in PPA) and MMSE score (higher in PPA). Percentage of pending diagnosis, delay between first consultation and first diagnosis and the number of different diagnoses before the diagnosis of interest were significantly higher in PPA group compared to AD group. Pharmacological and non-pharmacological treatments were significatively more recommended following PPA than AD diagnosis.ConclusionThis study improves the knowledge of PPA epidemiology and has the potential to help adopting appropriate public health service policies. It supports the hypothesis that PPA is diagnosed later than AD. The PPA diagnosis increases the prescription of non-pharmacological treatments, especially speech and language therapy (SLT) that is the main treatment available and most effective when at the initial stage.Trial registrationClinicalTrials.gov identifier NCT03687112